Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond

被引:6
|
作者
Schork, N. J. [1 ,3 ,4 ]
Nazor, K. [2 ]
机构
[1] Translat Genom Res Inst, Phoenix, AZ 85004 USA
[2] MYi Diagnost & Discovery, San Diego, CA USA
[3] J Craig Venter Inst, La Jolla, CA 92037 USA
[4] Univ Calif San Diego, San Diego, CA 92103 USA
来源
基金
美国国家卫生研究院;
关键词
PLURIPOTENT STEM-CELLS; OF-THE-ART; IPSC LINE; ACQUIRED-RESISTANCE; KINASE INHIBITION; PUBLIC RESOURCE; PATIENT IPSCS; N-OF-1; TRIALS; BIG DATA; GENERATION;
D O I
10.1016/bs.adgen.2017.06.001
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Individualized medicine, or the tailoring of therapeutic interventions to a patient's unique genetic, biochemical, physiological, exposure and behavioral profile, has been enhanced, if not enabled, by modern biomedical technologies such as high-throughput DNA sequencing platforms, induced pluripotent stem cell assays, biomarker discovery protocols, imaging modalities, and wireless monitoring devices. Despite successes in the isolated use of these technologies, however, it is arguable that their combined and integrated use in focused studies of individual patients is the best way to not only tailor interventions for those patients, but also shed light on treatment strategies for patients with similar conditions. This is particularly true for individuals with rare diseases since, by definition, they will require study without recourse to other individuals, or at least without recourse to many other individuals. Such integration and focus will require new biomedical scientific paradigms and infrastructure, including the creation of databases harboring study results, the formation of dedicated multidisciplinary research teams and new training programs. We consider the motivation and potential for such integration, point out areas in need of improvement, and argue for greater emphasis on improving patient health via technological innovations, not merely improving the technologies themselves. We also argue that the paradigm described can, in theory, be extended to the study of individuals with more common diseases.
引用
收藏
页码:81 / 113
页数:33
相关论文
共 50 条
  • [32] Beyond mainstream medicine - dialogue towards a new paradigm for health
    Llewellyn, Catherine
    [J]. EUROPEAN JOURNAL OF PSYCHOTHERAPY & COUNSELLING, 2022, 24 (03) : 375 - 377
  • [33] Network medicine: a new paradigm for cardiovascular disease research and beyond
    Menche, Joerg
    [J]. CARDIOVASCULAR RESEARCH, 2017, 113 (10) : E29 - E30
  • [34] Evidence-Based Medicine and Rare Diseases
    Day, Simon
    [J]. RARE DISEASES EPIDEMIOLOGY, 2010, 686 : 41 - 53
  • [35] STERN,NS - RARE DISEASES IN INTERNAL MEDICINE
    PYKE, D
    [J]. PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1966, 59 (10): : 1050 - &
  • [36] Rare Diseases in the Dentistry, Oral and Maxillofacial Medicine
    Hanisch, M.
    [J]. GESUNDHEITSWESEN, 2019, 81 (03) : 245 - 245
  • [37] Personalized Medicine: What's in it for Rare Diseases?
    Halfmann, Sebastian Schee Genannt
    Mahlmann, Laura
    Leyens, Lada
    Reumann, Matthias
    Brand, Angela
    [J]. RARE DISEASES EPIDEMIOLOGY: UPDATE AND OVERVIEW, 2ND EDITION, 2017, 1031 : 387 - 404
  • [38] Precision medicine and rare diseases in pediatric urology
    Nordgren, Ann
    Lindstrand, Anna
    Wu, Hsi-Yang
    Fossum, Magdalena
    [J]. JOURNAL OF PEDIATRIC UROLOGY, 2023, 19 (03) : 335 - 338
  • [39] Rare diseases in the age of genomics and precision medicine
    Rios Leal, Juvenal A.
    Labbe Atenas, Tomas P.
    [J]. REVISTA MEDICA DE CHILE, 2019, 147 (04) : 530 - +
  • [40] Predictive medicine and biomarkers: the case of rare diseases
    Taruscio, Domenica
    Salvatore, Marco
    Magrelli, Armando
    Tomanin, Rosella
    [J]. PERSONALIZED MEDICINE, 2012, 9 (02) : 143 - 146